During the last week, Lexaria Bioscience (Nasdaq: LEXX) has come under pressure and we believe the pullback has created a great opportunity for investors.
The biotech company has been nothing short of an execution story and has several significant potential catalysts for growth. At current levels, we consider the business to be undervalued (based on market capitalization) and find the risk-reward profile to be favorable.
A key reason for our bullish view on Lexaria is related to the number of clinical and pre-clinical studies that are taking place. We are also favorable on the company’s focus on intellectual property (IP) and the size of its patent portfolio.
The biotech company operates a licensed in-house research laboratory and holds a robust IP portfolio with 28 patents granted and many more patents pending worldwide. We are bullish on the strength of the company’s IP portfolio and are favorable on how the management team continues to focus on this aspect of the business.
Over the next few months, we expect Lexaria to report on several important developments and we want our investors to be aware of the business after the pullback. When it comes to the company’s growth prospects, we are most excited about the opportunity associated with DehydraTECH-processed cannabidiol (CBD).
Last month, Lexaria reported additional findings from its human clinical study HYPER-H21-4 which demonstrated a potentially novel mechanism of action of its patented DehydraTECH-processed CBD capsule formulation in reducing blood pressure (BP). We are excited about the data that was released and believe the market underappreciates this aspect of the story.
Lexaria is investigating how DehydraTECH-processed CBD may benefit a wide range of patients who are suffering from debilitating conditions and we are favorable on this. From dementia to diabetes, DehydraTECH is currently being studied for a variety of conditions, and we find this to be significant. We believe the company is led by a management team that is focused on creating value for shareholders and are bullish on the direction the business is heading.
During the last few years, Lexaria has developed significantly more powerful versions of DehydraTECH-CBD which may offer even further enhanced CBD delivery orally or topically as compared to its compositions that were previously tested. We believe the technology has significantly improved following such studies and believe the market is not assigning enough value to the advancement of the business.
If you are interested in learning more about Lexaria Bioscience, please send an email to email@example.com with the subject “Lexaria Bioscience” to be added to our distribution list.
Company Relationship Disclosure
OTB is responsible for the OTB opinions provided in this disclosure except all sources or information provided by other parties were not verified or authenticated and OTB does not undertake to confirm or substantiate or be responsible for such information provided by other parties.
Any Content posted regarding a Profiled Issuer is not a solicitation or recommendation to buy, sell or hold securities. We cannot and do not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. All information should be independently verified. We are not responsible for errors or omissions in our publications, and any opinions expressed are subject to change, without notice. We do not, nor are we under any obligation to undertake due diligence or investigation or authenticate and verify whatsoever regarding Profiled Issuers or any Content posted in relation thereto and we do not receive any verification from the Profiled Issuer regarding the Content we disseminate. Similarly, while we endeavor to facilitate the provision of quality information, we are not responsible for any loss or damages caused or alleged to have been caused by its use nor verify or authenticate or update such information.
Pursuant to an agreement between Spotlight Media and Lexaria Bioscience we have been hired for a period of 30 days beginning February 9, 2023 and ending March 9, 2023 to publicly disseminate information about Lexaria Bioscience including on the Website and other media including Facebook and Twitter. We are being paid $2,000 per month by Lexaria Bioscience and were paid “ZERO” shares of unrestricted or restricted common shares. We plan to sell the “ZERO” shares of Lexaria Bioscience that we hold during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of Lexaria Bioscience in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information.
This article contains forward-looking statements within the meaning of applicable securities laws. All statements that are not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs regarding future performance are “forward-looking statements”. Forward-looking statements can be identified by the use of words such as “expects”, “does not expect”, “is expected”, “believes”, “intends”, “anticipates”, “does not anticipate”, “believes” or variations of these words, expressions or statements, that certain actions, events or results “may”, “could”, “would”, “might” or “will be” taken, will occur or will be realized. Such forward-looking statements involve risks, uncertainties and other known and unknown factors that could cause actual results, events or developments to differ materially from the results, events or developments expected and expressed or implied in such forward-looking statements. These risks and uncertainties include, but are not limited to, dependence on obtaining and maintaining regulatory approvals, including the acquisition and renewal of federal, provincial, state, municipal, local or other licenses, and any inability to obtain all necessary government authorizations, licenses and permits to operate and expand the Company’s facilities; regulatory or policy changes such as changes in applicable laws and regulations, including federal, state and provincial legalization, due to fluctuations in public opinion, industry perception of integrative mental health, including the use of psychedelic-assisted therapy, delays or inefficiencies or any other reason; any other factor or development likely to hamper the growth of the market; the Company’s limited operating and profitability track record; dependence on management; the Company’s need for additional financing and the effects of financial market conditions and other factors on the availability of capital; competition, including that of more established and better funded competitors; the impact of the Russia-Ukraine conflict on the global economy; the continued impact of the COVID-19 pandemic; and the need to build and maintain alliances and partnerships, including with research and development companies, customers and suppliers. These factors should be carefully considered, and readers are cautioned not to place undue reliance on forward-looking statements. Despite the Company’s efforts to identify the main risk factors that could cause actual measures, events or results to differ materially from those described in forward-looking statements, other risk factors may cause measures, events or developments to materially differ from those anticipated, estimated or intended. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in forward-looking statements. The Company does not undertake to revise forward-looking statements, even if new information becomes available as a result of future events, new facts or any other reason, except as required by applicable laws